Medicine and Dentistry
Neuroendocrine Tumor
100%
Neoplasm
76%
Overall Survival
30%
Pancreas Islet Cell Tumor
26%
Meta-Analysis
26%
Cancer
24%
Solid Malignant Neoplasm
20%
Diseases
19%
Malignant Neoplasm
17%
Surgery
15%
Medicare
14%
Biological Marker
14%
Lung Cancer
14%
Surveillance, Epidemiology, and End Results
13%
Childhood Cancer
13%
Umbrella Review
13%
Cancer Therapy
13%
Tuberous Sclerosis
13%
Adrenal Tumor
13%
Gemcitabine
13%
Lung
13%
Progression Free Survival
13%
Recurrence Free Survival
12%
Recurrent Disease
12%
Temozolomide
11%
Rectum Cancer
11%
Odds Ratio
11%
Paraganglioma
10%
Pheochromocytoma
10%
Fluorouracil
9%
Colorectal Carcinoma
9%
Fibrosis
9%
Systemic Therapy
9%
Immunotherapy
8%
Randomized Controlled Trial
8%
Ganglioglioma
8%
Pediatric Cancer
7%
Rare Tumor
7%
Prostate Cancer
7%
Pathologist
6%
Survival Estimate
6%
Neoadjuvant Therapy
6%
Enterochromaffin Like Cell
6%
Neuroendocrine Tumor
6%
Health Care Cost
6%
Tumor Diagnosis
6%
Lupus Erythematosus Panniculitis
6%
Immune Checkpoint Inhibitor
6%
Ewing Sarcoma
6%
Proton-Pump Inhibitor
6%
Keyphrases
Pancreatic Neuroendocrine Tumors (pNETs)
48%
Neuroendocrine Neoplasms
45%
Overall Survival
36%
Neuroendocrine Tumor
36%
Gemcitabine
26%
Tumor
24%
Older Adults
20%
Solid Tumors
18%
Colorectal Cancer
16%
Meta-analysis
15%
Confidence Interval
15%
Randomized Evidence
15%
Temozolomide
14%
Treatment-related
14%
Recurrence-free Survival
13%
Childhood Cancer
13%
Cancer Therapy
13%
Adrenal Tumor
13%
Complex mutations
13%
Tuberous Sclerosis Complex
13%
Institutional Experience
13%
TSC mutations
13%
Well-differentiated Pancreatic Neuroendocrine Tumor
13%
Umbrella Review
13%
Population-based Study
13%
Medicare Spending
13%
Histology
12%
Progression-free Survival
12%
PanNEN
12%
Tumor Patients
11%
Stable Disease
11%
Tumor Grade
11%
Surveillance Epidemiology
11%
Neoplasms
11%
Paraganglioma
11%
Pheochromocytoma
11%
Systemic Therapy
11%
Lung Cancer
10%
Recommended Phase 2 Dose
10%
Risk Factors
10%
Pancreas
10%
Dose Escalation
9%
Phase II Study
9%
Histopathological Features
9%
Metastasis
9%
5-fluorouracil (5-FU)
8%
Median Progression-free Survival
8%
Refractory Solid Tumors
8%
Leucovorin
8%
Odds Ratio
8%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
51%
Neuroendocrine Tumor
51%
Overall Survival
31%
Diseases
29%
Progression Free Survival
23%
Gemcitabine
20%
Solid Malignant Neoplasm
16%
Clinical Trial
15%
Biological Marker
14%
Pancreas Cancer
13%
Childhood Cancer
13%
Recurrent Disease
11%
Fluorouracil
11%
Pancreas Adenocarcinoma
10%
Randomized Controlled Trial
10%
Adverse Event
10%
Malignant Neoplasm
10%
Folinic Acid
10%
Chemotherapy
9%
Nausea
8%
Leukemia
8%
Adenocarcinoma
8%
Radioisotope
8%
Temozolomide
8%
Paclitaxel
8%
Stomatitis
7%
Receptor
7%
Irinotecan Sucrosofate
6%
Ulixertinib
6%
Phase I Trials
6%
Erlotinib
6%
Pembrolizumab
6%
Lutetium 177
6%
Dexamethasone
6%
Fibrosis
6%
Proteinase
6%
Pheochromocytoma
6%
Temsirolimus
6%
End Stage Renal Disease
6%
Dopamine Receptor D2
6%
Chemoradiation Therapy
6%
Paricalcitol
6%
Heart Disease
6%
Tumor Growth
6%
Gallium 68
6%
Rectum Cancer
6%
Paraganglioma
6%
Acute Lymphoblastic Leukemia
6%
Phase II Trials
6%
Chronic Lymphatic Leukemia
6%